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Since its introduction by Leksell, Gamma Knife radiosurgery (GKRS) has become increasingly popular as a management approach
for patients diagnosed with trigeminal neuralgia (TN). For this reason, we performed a modern review of the literature analyzing
theeﬃcacyofGKRSinthetreatmentofpatientswhosuﬀerfromTN.Forpatientswithmedicallyrefractoryformsofthecondition,
G K R Sh a sp r o v e nt ob ea ne ﬀective initial and repeat treatment option. Cumulative research suggests that patients treated a single
timewithGKRSexhibitsimilarlevelsoffacialpaincontrolwhencomparedtopatientstreatedmultipletimeswithGKRS.However,
patients treated on multiple occasions with GKRS are more likely to experience facial numbness and other facial sensory changes
when compared to patients treated once with GKRS. Although numerous articles have reported MVD to be superior to GKRS
in achieving facial pain relief, the ﬁndings of these comparison studies are weakened by the vast diﬀerences in patient age and
comorbidities between the two studied groups and cannot be considered conclusive. Questions remain regarding optimal GKRS
dosing and targeting strategies, which warrants further investigation into this controversial matter.
1.Introduction
Trigeminalneuralgia(TN)isadisorderofcranialnerve(CN)
V that results in severe episodes of shock-like or lancinating
pain in one or more of its three divisions (V1–V3). TN
can be classiﬁed into two categories based on etiology: clas-
sical and symptomatic [1]. Idiopathic TN and cases due to
vascular compression of CN V are categorized as classical
TN [1]. Patients diagnosed with symptomatic TN experience
trigeminal-related facial pain secondary to a brain tumor,
skull deformity, or multiple sclerosis (MS) [1]. Evidence
suggests that the majority of cases of TN are the consequence
of focal compression of the entry zone of the root of the
trigeminal nerve [2], while only 2% of cases are observed
in patients diagnosed with MS [3]. Other than excruciating
facial pain, there are no other direct medical symptoms
associated with TN, and the condition does not decrease
life expectancy. However, many patients with TN struggle
with accomplishing tasks that aﬀect quality of life, which is
how this disorder elicits a negative impact on the social and
mental wellness of the patients who suﬀer from this illness.
Following the diagnosis of TN, pharmacotherapy is often
the initial management approach in achieving facial pain
control. However, many patients experience only limited
relieffrommedicationorareunabletoendurethesideeﬀects
of the prescribed drugs, and in turn seek neurosurgical inter-
vention. Currently, surgical approaches include microvas-
cular decompression (MVD) or a number of techniques
that target the trigeminal ganglion or root which involve
the destruction or blockage of portions of those anatomical
structures [1, 2]. Although the neurosurgical modalities are
preferred in many clinical situations and have proven to be2 International Journal of Otolaryngology
eﬀective in achieving initial pain control, they are known
to come with a variety of complications, and facial pain
recurrence is likely [4].
Stereotactic radiosurgery (SRS) has proven to be an
eﬀective management approach for patients with medically
[5] and surgically [6] refractory TN as a primary and repeat
treatmentmodality.Theuseofradiosurgeryinthetreatment
of TN dates back to Sweden in the 1950’s, where Professor
Lars Leksell performed radiogangliotomies directed at the
gasserian ganglion [7]. Since the time of Leksell, advance-
ments in radiosurgery and imaging technologies has led to
the increasing popularity of SRS as a treatment option for
patients with TN. One form of SRS that can be delivered
to a patient is through a machine called the Gamma Knife
(GK). The GK device is a cobalt-60-based machine, with 201
separate 4 to 18mm collimator openings, that emits multiple
gamma rays that converge on a target speciﬁed by computer
planning. For speciﬁc medication intolerable patient subsets,
Gamma Knife radiosurgery (GKRS) can be used as an initial
management approach, or as a secondary management
approach following radiosurgery or one or more of the
various surgical modalities. As the evidence examining the
role of GKRS in the management of patients with TN
is increasing, it is of utmost importance for physicians to
understand the criteria associated with GKRS, so that the
optimal course of treatment for their patients can be pre-
scribed.
An evidence-based review on the evaluation and treat-
ment of TN by Gronseth et al. [8] found Level C evidence
indicating that gasserian ganglion percutaneous techniques,
GKRS, and MVD may be considered for facial pain manage-
ment for medically refractory patients. However, questions
remain regarding optimal treatment modalities in speciﬁc
patient subsets. For this reason, the goal of this paper is
to provide a modern review of the literature thoroughly
analyzing the eﬃcacy of GKRS in the treatment of patients
with TN, as well as evaluating the treatment planning and
methods associated with this evolving modality.
2. Review of Gamma Knife Radiosurgery for
TrigeminalNeuralgia
2.1. Literature Search Strategy. To identify contemporary
studies assessing the clinical outcomes of patients treated
withGKRSforTN,aPubMedsearchfrom2006toApril2011
wasperformed.Keywordsforsearchincluded“GammaKnife
OR Gamma Knife radiosurgery OR stereotactic radiosurgery
trigeminal neuralgia OR tic douloureux.” Studies analyzed
in this review included retrospective cohort studies and
prospective cohort studies with ≥5 evaluated patients. Stud-
iespublishedonlyinabstractformandstudiespublishedina
languageotherthanEnglishwereexcludedfromouranalysis.
Due to our broad search strategy and the vast amount of
world literature, references from existing review articles were
also selected and analyzed for study inclusion eligibility.
2.2. Clinical Outcomes of Patients Undergoing a Single
Gamma Knife Treatment. We reviewed a total of 19 studies
[4, 5, 9–25] analyzing the eﬃcacy of patients with TN
who were treated once with GKRS (Table 1). Thirteen of
the 19 evaluated studies [4, 5, 9–19] utilized the Barrow
Neurological Institute (BNI) pain intensity scale [26]a sa
measurement of response to treatment (See Section 3). One
of the studies [18] included patients diagnosed with atypical
TN. Of these 13 studies, only two [9, 13] analyzed patients
treated with GKRS as an initial management approach.
With a median followup of 31 months, Sheehan et al. [9]
classiﬁed 87% of patients in BNI class I-IIIb, while Chen et
al. [13] classiﬁed 91% of patients in BNI class I-IIIb (median
followup = 15 months). Chen et al. [13] also reported that
ﬁve of the 44 patients (11%) treated with GKRS developed
hypoesthesia following the procedure.
Theother11BNIpainintensityscalestudieswereviewed
included patients where previous surgical procedures were
performed in a fraction of patients [4, 5, 10–12, 15–19]o r
all patients [14]. Of the 10 studies where previous surgical
procedures were performed in a fraction of patients, nine
reported outcomes in terms of categorizing patients in BNI
class I-IIIb [4, 5, 10–12, 15–18]. Speciﬁcally, Riesenburger
et al. [10] classiﬁed 58.6% of patients in BNI class I-IIIb
(median followup = 48 months), Kondziolka et al. [5]
classiﬁed 71% of patients in BNI class I-IIIb at three years,
Dhople et al. [18] classiﬁed 72% of patients in BNI class
I-IIIb (median followup = 29 months), Han et al. [11]
classiﬁed 76.7% of patients in BNI class I-IIIb (mean
followup = 58 months), Dhople et al. [17] classiﬁed 81% of
patients in BNI class I-IIIb (median followup = 5.6 years),
Matsuda et al. [16] classiﬁed 82% of patients in BNI class
I-IIIb (median followup = 37 months), Little et al. [15]
classiﬁed 83% of patients in BNI class I-IIIb (median
followup = 6.3 years), Dellaretti et al. [4] classiﬁed 89.5% of
patients in BNI class I-IIIb (mean followup = 20.3 months),
and Park and Hwang [12] classiﬁed 94% of patients in BNI
class I-IIIb with a minimum followup of 3 years. Pan et al.
[19] reported clinical outcomes with respect to BNI class
I, which contained only 5.7% of patients. The study that
evaluated GKRS where previous surgical procedures were
performed in 100% of patients classiﬁed 85% of patients in
BNI class I-IIIb, with a median followup of 36 months [14].
We also reviewed two studies that used the excellent-
good-fair-poor (EGFP) categorical scale to assess patient
outcomes [20, 21] (See Section 3). Azar et al. [21]t r e a t e d3 0
patients with TN with GKRS at Iran Gamma Knife Center
between 2006 and 2007. The authors reported that 40% of
patients had an excellent outcome, 10% of patients had a
good outcome, 33% of patients had a fair outcome, and 17%
of patients had a poor outcome following the procedure.
Approximately 13% of patients reported facial numbness
related to GKRS. Sekula et al. [20]a n a l y z e d2 9c o n s e c u t i v e
patients who underwent MVD after failed GKRS. After
surgery, 15 patients (54%) reported an excellent outcome,
one patient (4%) reported a good outcome, two patients
(7%) reported a fair outcome, and 10 patients (36%)
reported a poor outcome. The complications from MVD
included facial numbness in six patients (21%), dysesthesias
in three patients (11%), and delayed facial palsy in one
patient (4%).International Journal of Otolaryngology 3






(Gy) Study endpoints Results
Patients with vessel impingement 59%
Pain relief in patients with or w/o
vascular impingement P = NS
BNI score I 57%
Sheehan et al. [9] (2010) BNI Median: 84 BNI score II 17%
BNI score III 13%
BNI score IV 10%
BNI score V 2%
BNI score I 43%
Chen et al. [13] (2010) BNI 90 BNI score I–IIIb 91%
Patients with hypoesthesia 11%
BNI score I 32.1%
BNI score II 3.8%
Riesenburger et al. [10] (2010) BNI Median: 80 BNI score IIIa 1.9%
BNI score IIIb 20.8%
BNI score IV 41.5%
Patients with facial numbness 36%
1-y BNI score I–IIIb 80%
3-y BNI score I–IIIb 71%
Kondziolka et al. [5] (2010) BNI 60–90 5-y BNI score I–IIIb 46%
10-y BNI score I–IIIb 30%
Patients with facial numbness or
paresthesia 10.5%
BNI score I 22%
Dhople et al. [18] (2007) BNI Median: 75 BNI score II 6%
BNI score III 44%
Patients with trigeminal dysfunction 19%
BNI score I–IIIb 76.7%
Han et al. [11] (2009) BNI Mean: 79.7 Patients with pain recurrence 52.2%
Patients with radiation-induced cranial
neuropathy 15%
1-y actuarial rate of freedom from
treatment failure 60%
3-y actuarial rate of freedom from
treatment failure 41%
Dhople et al. [17] (2009) BNI Median: 75
5-y actuarial rate of freedom from
treatment failure 34%
7-y actuarial rate of freedom from
treatment failure 22%
Superior response duration in patients
w/o prior surgery P<0.02
Patients with facial numbness 6%
BNI score I-IIIb 82%
Matsuda et al. [16] (2010) BNI 80–90 Patients with trigeminal nerve
dysfunction 41.3%
7-y GKRS initial treatment pain-free rate 45%
Little et al. [15] (2008) BNI 70–90 7-y GKRS secondary treatment pain-free
rate 10%
Patients with bothersome facial







(Gy) Study endpoints Results
1-y complete pain relief rate 83.1%
2-y complete pain relief rate 70.9%
Dellaretti et al. [4] (2008) BNI Mean: 85.1 3-y complete pain relief rate 62.5%
Superior pain relief in patients w/o prior
surgery P<0.05
Patients with trigeminal dysfunction 21%
BNI score I 17.6%
BNI score II 17.6%
Park and Hwang [12] (2011) BNI 80–90 BNI score IIIa 41.2%
BNI score IIIb 17.6%
BNI score V 5.9%
Patients with trigeminal nerve
dysfunction 23.5%
BNI score I 5.7%
Pan et al. [19] (2010) BNI 80 Patients with pain recurrence 44.2%
Patients with facial numbness 9.6%
1-y BNI score I 26%
Kano et al. [14] (2010) BNI 60–90 1-y BNI score 1-IIIb 85%




Azar et al. [21] (2009) EGFP 90 Fair outcome 33%
Poor outcome 17%
Patients with facial numbness 13%
Excellent outcome 54%
Good outcome 4%
Sekula et al.∗ [20] (2010) EGFP NR Fair outcome 7%
Poor outcome 36%
Patients with facial numbness 21%
Patients with dysesthesias 11%
Patients with complete pain relief 83%
R´ egis et al. [22] (2006) Median: 85 Patients with facial numbness 6%
Patients with hypesthesia 4%
Patients with complete pain relief 32.6%
Knafo et al. [23] (2009) 80 Patients with signiﬁcant pain relief 77.6%
Patients with sensory side eﬀects 14.9%
Patients pain-free w/o medication 61%
Longhi et al. [24] (2007) 75–95 Patients pain-free with medication 29%
Patients with no pain relief 10%
Patients with side eﬀects 9%
Patients with complete pain relief 29.9%
Kang et al. [25] (2008) Mean: 84.3 Patients with pain improvement 49.4%
Patients with side eﬀects 15.6%
BNI: Barrow Neurological Institute; EGFP: excellent-good-fair-poor; GKRS: Gamma Knife radiosurgery; MVD: microvascular decompression; NR: not
reported; NS: nonsigniﬁcant.
∗Study includes patients treated with MVD after failed GKRS.International Journal of Otolaryngology 5
Four of the 19 studies we evaluated [22–25] used other
methodologies in determining the eﬀectiveness of GKRS.
In a prospective controlled trial, R´ egis et al. [22]a n a l y z e d
100 patients with TN treated with GKRS and reported that
83 patients (83%) were completely pain free, 58 of which
(58%) discontinued all medication following the procedure
(minimumfollowup=12months).Tenpatients(10%)expe-
rienced radiation-induced complications, which included
facial paresthesia or hypesthesia. Knafo et al. [23]p e r f o r m e d
a study investigating the short-term eﬃcacy of GKRS in
67 patients with medically refractory TN. The authors per-
formed followup assessments at 2, 4, and 6 months. Overall,
77.6% of patients witnessed some degree of pain relief,
with 32.6% of those patients becoming completely pain
free. Of the 67 patients, 10 (14.9%) experienced complica-
tions from the procedure, which included hypoesthesia and
paresthesia. Longhi et al. [24] treated 160 patients with TN
with GKRS (mean followup = 37.4 months). Sixty eight
patients (42.5%) underwent prior invasive treatments. In
clinical analysis, it was found that 61% of patients were
pain free without medication, 29% of patients were pain free
with medication, and 10% of patients did not respond to
GKRS. The observed side eﬀects were paresthesia (6.25%)
and hypoesthesia (2.5%). Kang et al. [25]t r e a t e d7 7p a t i e n t s
withidiopathicTNwithGKRS.Thirtyeightpatients(49.4%)
exhibited some level of pain improvement following GK
treatment, with 23 of those patients (29.9%) reporting a
pain-free outcome. Twelve patients (15.6%) experienced
complications, which were reported to be mild facial sensory
changes and mild facial nerve dysfunction.
2.3. Clinical Outcomes of Patients Undergoing Multiple
Gamma Knife Treatments. A sG K R Sh a sp r o v e nt ob ea ne f -
fective initial treatment for TN, occasions (>1) with GKRS.
Wereviewedsixstudiesevaluatingpatientstreatedmorethan
once with GKRS [27–32]( Table 2). Of these six articles, two
[29, 32] utilized the BNI pain intensity scale [26]. Gellner et
al. [32] evaluated 21 patients treated on two occasions with
GKRS. Ten patients (48%) had undergone previous surgical
procedures. Sixteen patients (76.2%) exhibited compelling
improvements and were placed in BNI class I-II. Huang et
al. [29] analyzed 65 medically refractory patients with TN
whoweretreatedwithGKRSasasecondtreatmentmodality.
Of these 65 patients, 30 (46%) had undergone GKRS as an
initialmanagementapproach.Theauthorsplaced22patients
(34%) in BNI class I, 11 patients (17%) in BNI class II, four
patients (6%) in BNI class IIIa, and ﬁve patients (8%) in BNI
class IIIb. Overall, with a median followup of 64 months,
65% of patients reported successful results in terms of pain
control rates.
A total of three of the six reviewed studies evaluated
patients using the EGFP categorical scale [28, 30, 31]. Aubu-
chon et al. [31] analyzed 37 patients treated a second time
with GKRS for recurrent TN and reported that 17 patients
(46%) achieved excellent pain relief, nine patients (24%)
achieved good pain relief, ﬁve patients (14%) achieved
fair pain relief, and six patients (16%) achieved poor pain
relief. However, the authors concluded that 57% of patients
experienced some form of trigeminal dysfunction following
repeat radiosurgery. Similar to the results reported by
Aubuchon et al. [31], Huang et al. [28]t r e a t e d2 8p a t i e n t s
with repeat GKRS and reported that 12 patients (43%)
exhibited excellent pain relief, ﬁve patients (18%) exhibited
good pain relief, and two patients (7%) exhibited fair pain
relief. In addition, the authors found a statistically signiﬁcant
(P = 0.047) correlation between cumulative radiation doses
>115Gy and facial numbness. In a separate study, Huang et
al. [30] evaluated the eﬃcacy of MVD following failed repeat
GKRS. Speciﬁcally, a total of eight patients underwent MVD
a mean of 7.6 months following repeat GKRS. Of the eight
patients, seven (87.5%) were completely pain free at a mean
of 21 months following neurosurgery. This data supports the
use of MVD if multiple GK procedures are deemed ineﬀec-
tive.
Kimball et al. [27] treated 53 patients with repeat GKRS
and analyzed the patients not lost during followup using
the Marseille scale [22], which categorizes patients into one
of ﬁve classes, with a higher class statistically indicating a
worse prognosis for the patient. With a mean followup of 42
months, 20 patients (43.5%) were categorized in Marseille
class I-II, six patients (13%) were categorized in Marseille
class III-IV, and 20 patients (43.5%) were categorized in
Marseille class V. The authors also reported a statistically
signiﬁcant (P = 0.047) correlation between facial numbness
and superior long-term pain relief. A total of 22 patients
(48%) experienced trigeminal dysfunction of any kind, while
21 patients (46%) experienced numbness in the face.
2.4. Clinical Outcomes of Patients Undergoing Single versus
Multiple Gamma Knife Treatments. S i n c eG K R Sc a nb ep e r -
formed as both initial and salvage treatment options for pa-
tients who suﬀer from TN, its eﬃcacy has been compared
in patients who undergo one versus multiple radiosurgery
procedures. We reviewed eight studies to further examine
this matter [3, 33–39]( Table 3). Four of the eight studies
utilized the BNI pain intensity scale [26] to evaluate patient
outcomes [3, 33–35]. Verheul et al. [33] performed 450
GK procedures in 365 patients. With a median followup
of 28 months, it was reported that 75%, 60%, and 58% of
patients with idiopathic TN had BNI scores of I–IIIb at 1, 3,
and 5 years, respectively. The 1-, 3-, and 5-year-BNI scores
of I–IIIb in patients with MS-related TN were 56%, 30%,
and 20%, respectively. The authors concluded that repeat
GKRS exhibited similar success rates when compared to
the initial procedure. Similar to Verheul et al. [33], Park
et al. [34] did not ﬁnd diﬀerences in terms of time to
initial response, time to pain recurrence, and overall pain
relief when comparing patients who underwent one versus
two GK treatments. However, it was observed that patients
who received two GK treatments were more likely to have
facial sensory changes when compared to patients treated a
single time with radiosurgery. Little et al. [35]p e r f o r m e da
study where 79 patients with typical TN were treated with
GKRS as a salvage procedure. Twenty-one patients (27%)
underwent GKRS as an initial modality. Approximately ﬁve6 International Journal of Otolaryngology









BNI score I 47.6%
Gellner et al. [32] (2008) BNI Mean: 74.3 BNI score II 28.6%
BNI score III 23.8%
BNI score I 34%
BNI score II 17%
BNI score IIIa 6%
Huang et al. [29] (2010) BNI Mean: 49 BNI score IIIb 8%
1-y pain control rate 74%
2-y pain control rate 71%
3-y pain control rate 66%
Facial numbness 17%
Excellent pain relief 46%
Good pain relief 24%
Aubuchon et al. [31] (2010) EGFP Mean: 84.4 Fair pain relief 14%
Poor pain relief 16%
Trigeminal nerve dysfunction 57%
Excellent pain relief 43%
Huang et al. [28] (2006) EGFP Mean: 52 Good pain relief 18%
Fair pain relief 7%
Facial numbness 36%
Marseille class I-II 43.5%
Kimball et al. [27] (2010) Marseille 70 Marseille class III-IV 13%
Marseille class V 43.5%
Facial numbness 46%
BNI: Barrow Neurological Institute; EGFP: excellent-good-fair-poor; GKRS: Gamma Knife radiosurgery.
years following salvage GKRS, the authors reported that
50% of patients experienced pain relief and 20% of those
patients were completely pain free. In addition, a statistically
signiﬁcant (P = 0.029) correlation between GKRS failure
andpriorMVDwasfound.Zorroetal.[3]treated37patients
(78% had failed prior surgery) with MS-related TN with
GKRS. Nine patients (24%) underwent GKRS as their ﬁrst
procedure. The reported 1, 3, and 5 year BNI scores of I–IIIb
were 82.6%, 73.9%, and 54%, respectively.
The other four studies we reviewed utilized the EGFP
categorical scale as a measurement of response to treatment
[36–39]. Two of the evaluated studies [36, 37]w e r ec o n -
ducted by Fountas et al. and analyzed patients treated with
GKRS for idiopathic TN based on whether or not they had
undergone previous surgical or radiosurgical procedures for
facial pain control. One of the studies evaluated 106 patients
(19 previous radiosurgery procedures) and concluded that
the treatment group without a previous history of surgical
or radiosurgical procedures exhibited superior clinical out-
comes, with 1-year and 2-year complete pain relief rates of
82.5% and 78%, respectively [36]. The 1-year and 2-year
completepainreliefrateinthepatientgroupwithahistoryof
surgical or radiosurgical procedures was 69.4% and 63.5%,
respectively [36]. As expected, similar results were found
in the other study by Fountas et al. [37]; however, no
priorradiosurgicalprocedureswereperformedinthepatient
group with a history of prior procedures. Huang et al. [38]
conducted a study where 89 patients with idiopathic TN
were treated with GKRS as an initial management approach,
20 of which underwent a subsequent GKRS procedure for
facial pain recurrence. Following the initial radiosurgical
procedure, 50 patients (56%) had an excellent response, 12
patients (13.5%) had a good response, and 7 patients (7.9%)
had a fair response. Following the second radiosurgical pro-
cedure, 11 patients (55%) had an excellent response and one
patient(5%)hadagoodresponse.Inaseparatestudy,Huang
et al. [39] assessed 21 patients with benign tumor-related TN
who were treated with GKRS as an initial or repeat proce-
dure. Following the initial GK procedure to the tumor, 12
patients (57%) had an excellent response and 1 patient (5%)
had a good response. A total of eight patients were treated
with a subsequent GKRS procedure targeted at the ipsilateral
trigeminal root or ganglion due to facial pain recurrence.
Following the second radiosurgical procedure, the authors
reported four patients (50%) with an excellent response.
2.5.ComparisonStudies. Weidentiﬁedsixstudiescomparing
patients treated with GKRS with patients treated with oneInternational Journal of Otolaryngology 7





GKRS max dose (Gy) Study endpoints Results
BNI scores of I–IIIb at 1-y for idiopathic TN 75%
BNI scores of I–IIIb at 3-y for idiopathic TN 60%
BNI scores of I–IIIb at 5-y for idiopathic TN 58%
Verheul et al. [33] (2010) BNI 1st treatment: 80
2nd treatment: 80
BNI scores of I–IIIb at 1-y for MS-related TN 56%
BNI scores of I–IIIb at 3-y for MS-related TN 30%
BNI scores of I–IIIb at 5-y for MS-related TN 20%
5-y idiopathic retreatment pain relief rate 75%
5-y MS retreatment pain relief rate 46%
Pain outcome in primary versus secondary GKRS P = NS





Primary GKRS facial numbness 21%
Secondary GKRS facial numbness 45.8%
BNI score of I–III at 1-y 75%
Patients requiring additional surgery 41%
Little et al. [35] (2009) BNI 1st treatment: 80
2nd treatment: 40–50 Patients with mild facial numbness 76%
Patients with bothersome facial numbness 8%
Patients with eye symptoms 12%
BNI scores of I–IIIb at 1-y 82.6%
Zorro et al. [3] (2009) BNI Median: 80 BNI scores of I–IIIb at 3-y 73.9%
B N Is c o r e so fI – I I I ba t5 - y 5 4 %
Patients with facial sensory dysfunction 5.4%
1-y no previous treatment excellent outcome rate 82.5%
1-y previous treatment excellent outcome rate 69.4%
Fountas et al. [36] (2007) EGFP Median: 80 2-y no previous treatment excellent outcome rate 78%
2-y previous treatment excellent outcome rate 63.5%
No previous treatment paresthesia rate 15.8%
Previous treatment paresthesia rate 16.3%
1-y no previous treatment excellent outcome rate 80.8%
1-y previous treatment excellent outcome rate 69.2%
Fountas et al. [37] (2006) EGFP Median: 80 2-y no previous treatment excellent outcome rate 64%
2-y previous treatment excellent outcome rate 11.5%
No previous treatment facial numbness rate 17.3%
Previous treatment facial numbness rate 16%
1st treatment excellent outcome rate 56%
1st treatment good outcome rate 13.5%





1st treatment fair outcome rate 7.9%
2nd treatment excellent outcome rate 55%
2nd treatment good outcome rate 5%
Facial numbness associated with repeat GKRS P = 0.007
Huang et al. [39] (2008) EGFP Mean: 60.7 Excellent outcome rate after GKRS to the tumor 57%
Excellent outcome rate after GKRS to CN V 50%
BNI: Barrow Neurological Institute; CN: cranial nerve; EGFP: excellent-good-fair-poor; GKRS: Gamma Knife radiosurgery; NS: nonsigniﬁcant.8 International Journal of Otolaryngology
Table 4: Comparison studies.
Author, surgery type (year) GKRS max dose (Gy) Study endpoints Surgery GKRS P value
Initial actuarial pain-free rate 100% 78%
0.0002∗ Linskey et al. [2], MVD (2008) 80–90 2-y actuarial pain-free rate 88% 50%
5-y actuarial pain-free rate 80% 33%
12-mo complete pain relief rate 68% 58% 0.089∗
Brisman [40], MVD (2007) 75 18-mo complete pain relief rate 68% 24%
Patients requiring retreatment 4.2% 18% NS
BNI Grade I-II classiﬁcation 63% 56% NR
Oh et al. [41], MVD (2008) Mean: 77.8 Patients with pain recurrence 11.1% 11.1% NR
TN complexity grade 3 5.8 <0.001
Aryan et al. [42], MVD (2006) 90 Average response following treatment 3.4 2.4 0.017
Patient satisfaction 8.7 6.4 0.02
Pollock and Schoeberl [43],
PFE (2010)
Median: 85
1-y pain-free rate 84% 66% 0.003∗
4-y pain-free rate 77% 56%
Retreatment rate 15% 35% 0.009
Pollock and Stein∗∗ [44],
PFE (2010) Median: 76.1 Patients treated with additional
surgery 22% 48% 0.02
BNI: Barrow Neurological Institute; GKRS: Gamma Knife radiosurgery; MVD: microvascular decompression; NR: not reported; NS: nonsigniﬁcant; PFE:
posterior fossa exploration; TN = trigeminal neuralgia.
∗P value indicates overall pain-free levels.
∗∗Data includes patients treated with ≥3 prior operations.
of the various surgical modalities [2, 40–44]( Table 4). The
authors of this review acknowledge the importance of percu-
taneous techniques in the management of TN; however, our
modern literature search predominantly yielded comparison
studies analyzing the eﬃcacy of MVD when compared to
GKRS.Speciﬁcally,fourofthesixstudies[2,40–42]anal yz ed
patients treated with GKRS against patients treated with
MVD. Linskey et al. [2] prospectively evaluated a total
of 80 patients with typical TN. No previous procedures
were performed on the patients constituting this study.
Speciﬁcally, 36 were treated with MVD (45%), while 44
were treated with GKRS (55%). The MVD treatment arm
statistically diﬀered from the GKRS treatment arm with
r e s p e c tt oa g e( m e d i a no f5 4v e r s u s7 4y e a r s ) ,p r e o p e r a t i v e
symptom duration (median of 2.6 versus 7.5 years), and
the presence of major comorbidities (2.8 versus 58.3%).
The mean followup time was determined to be 3.4 ± 2.1
years. The authors reported that patients treated with MVD
exhibited superior levels of initial (100%), 2 year (88%),
and 5 year (80%) actuarial pain-free rates when compared
to the patients treated with GKRS (78, 50, and 33%, resp.),
with a P value of 0.0002. In addition to increased levels of
patient satisfaction, as reported by required patient surveys,
the MVD treatment group also had a decreased level of
permanent mild (5.6%) and severe sensory loss (0%) when
compared to the GKRS treatment group (6.8% and 2.3%,
resp.). Two patients (5.6%) in the MVD group experienced
permanent mild paresthesias or numbness, one (2.8%)
patient experienced a cerebrospinal ﬂuid leak from the
wound, and one patient (2.8%) experienced hearing loss and
diplopia. Three patients (6.8%) in the GKRS group experi-
encedpermanentmildparesthesiasornumbness,onepatient
(2.3%) experienced a more permanent sensory numbness,
andonepatient(2.3%)experiencedatransientheadacheand
nausea following the GK procedure.
Brisman [40] compared 24 patients treated with MVD
with 61 patients treated with GKRS. All patients were
diagnosed with typical TN and did not undergo previous
GK or MVD procedures. It was reported that patients treated
withMVDexhibited superiorlevelsofcompletepainreliefat
12(68%)and18months(68%)whencomparedtotheGKRS
group, who’s complete pain relief rate was 58% at 12 months
and 24% at 18 months (P = 0.089). The treatment arms
did not statistically diﬀer in terms of ≥90% pain relief at 12
and18months.Nopermanentcomplicationswereobserved.
This study could be criticized due to the large diﬀerence in
the number of patients constituting the two treatment arms.
Oh et al. [41] evaluated a total of 45 elderly patients
(>65 years of age) diagnosed with idiopathic TN who
were treated with either MVD (27 patients) or GKRS (18
patients).ItwasreportedthatthreeMVDpatients(11%)and
three GK patients (17%) underwent previous percutaneous
procedures. The mean followup period was reported to be
35.9 months for the MVD group and 33.1 months for the
GKRS group. According to the BNI pain intensity scale [26],
the MVD group had a superior prognosis, with 17 patients
(63%) classiﬁed in BNI class I-II compared with the 10
patients (56%) in the GKRS group classiﬁed in BNI class I-
II. The two groups did not diﬀer in terms of pain recurrence
during followup. The observed complications following
MVD included constant headache in 11 patients (40.7%),
facial paresthesia in ﬁve patients (18.5%), paresthesia of theInternational Journal of Otolaryngology 9
tongueintwopatients(7.4%),infectionatthesiteofincision
in one patient (3.7%), an acute subdural hemorrhage in
one patient (3.7%), temporary hearing loss in one patient
(3.7%), and otitis media with cerebrospinal leakage in one
patient (3.7%). Two patients (11%) in the GKRS group
experienced paresthesia.
Aryan et al. [42] compared the clinical outcomes of
19 patients treated with MVD with 15 patients treated
with GKRS. Patients diagnosed with symptomatic TN were
excluded from this study. Nine GK patients (60%) and four
MVD patients (21%) underwent previous surgical proce-
dures. The treatment arms statistically diﬀered (P = 0.0005)
with respect to mean patient age, with the mean age of the
GKRS group exceeding the MVD group by 13 years (74
versus 61 years). The median followup was determined to be
17 months. The authors determined clinical results by using
the EGFP categorical scale. In addition, patient satisfaction
was graded on a scale of 1 (unsatisﬁed) to 10 (completely
satisﬁed). It was reported that the mean TN complexity
grade was statistically diﬀerent (P<0.001) between the
treatment arms (GK = 5.8; MVD = 3). The average response
following the procedure was determined to be 3.4 for the
MVD group and 2.4 for the GKRS group (P = 0.017). Also,
it was found that the satisfaction score for the MVD group
was superior to the GKRS group (8.7 versus 6.4), with a
P value of 0.02. The authors reported a statistically signiﬁ-
cant correlation between TN complexity grade and clinical
response (P<0.001), as well as TN complexity grade and
patient satisfaction (P<0.001).
To date, no randomized trials have been conducted ana-
lyzingtheoutcomesofpatientswithTNwhoaretreatedwith
MVD compared to GKRS. In a large review on TN man-
agement, Zakrzewska and Linskey [45] found evidence that
MVD is an eﬀective treatment for long-term facial pain relief
but comes with an increased risk of ipsilateral hearing loss.
In addition, the authors concluded that single-dose SRS is an
eﬀective treatment for long-term facial pain relief but puts
patients at risk for facial numbness or facial paresthesias.
Investigation into this matter in the form of a randomized
controlled trial would provide the best evidence in terms of
facial pain relief and procedure-related complications.
In addition, we reviewed two studies comparing patients
treated with GKRS with patients treated with posterior fossa
exploration (PFE) [43, 44], both of which were conducted
by Pollock and colleagues at the Mayo Clinic College of
Medicine. One of the studies [43] was a speciﬁc prospective
comparison of 91 patients treated with PFE and 49 patients
treated with GKRS for idiopathic TN as an initial manage-
ment approach. The treatment arms statistically diﬀered in
terms of age (GKRS = 67.1 years; PFE = 58.2 years), with a P
value <0.001. The median followup time was 38 months. It
was reported that patients treated with PFE were more likely
to be pain free and oﬀ medications at 1 year (84%) and 4
years (77%) when compared to the GKRS group (66 and
56%, resp.) (P = 0.003). Retreatment for recurrent facial
pain was performed in 15% of the patients in the PFE treat-
ment arm and 35% of patients in the GKRS treatment arm
(P = 0.009). Also, it was found that nonbothersome facial
numbness occurred more frequently in the GKRS group
(P = 0.04). An additional study from the Mayo Clinic
evaluated patients with recurrent TN who underwent 3
or more surgical procedures [44]. The authors reported
that patients treated with PFE exhibited superior levels of
complete pain relief at 3 years of followup when compared
to patients treated with GKRS, balloon compression, and
glycerol rhizotomy (P<0.01) and underwent additional
surgery for recurrent facial pain less often when compared to
patients treated with the other modalities (P = 0.02). Clin-
ical outcomes did not diﬀer between patients treated with




of tools, which include GKRS, CyberKnife technology, and
linear accelerator (LINAC)-based treatment. Our analysis
yielded one study whose primary endpoint was to devise
a method using CyberKnife treatment planning that would
mimic the dosimetric characteristics of the GK treatment
plan in ﬁve patients undergoing radiosurgery for TN [46].
The position of the trigeminal nerve was determined using
computed tomography cisternography. Both the isodose
lines and critical structures were identiﬁed using the GKRS
treatment plan and were transferred to the CyberKnife treat-
mentplanningsystem.Itwasreportedthattheaveragelength
of the trigeminal nerve receiving a dose of 60Gy was 4.5mm
for the GK, 4.5mm for the nonisocentric CyberKnife, and
4.4mm for the isocentric CyberKnife. The authors found
it more diﬃcult to minimize the dose to critical structures
when using CyberKnife technology. Also, the dose falloﬀ of
GKRSwasfoundtobesteeperwhencomparedtoCyberKnife
technology due to, what the authors hypothesized, the large
number of gamma rays produced which converge on the
focal point with precision.
As previously mentioned, the GK machine’s primary
functional unit is cobalt-60, which is used to emit photon
energy through 201 separate 4 to 18mm collimator openings
that converge on a target speciﬁed by a treatment planning
system. Balamucki et al. [47] performed a study examining if
the half life of cobalt (5.26 years) relates to the outcomes for
patients being treated for TN with GKRS. The authors col-
lecteddataon239GKRSproceduresperformedattheirinsti-
tution between 1999 and 2004. Patient surveys were used to
measure responses to radiosurgery. With the followup time
ranging from one to six months, it was reported that 80% of
patients experienced some degree of pain relief and that 56%
of those patients were pain free. The authors concluded that
clinical outcomes remained consistent during the ﬁrst half
life of cobalt-60.
3.2. Dosing. An area of controversy in the treatment of
patients with TN is deﬁning the optimal maximum radio-
surgery dose that can be delivered to speciﬁc patient subsets.
We analyzed ﬁve studies whose primary endpoint was to
assess GKRS-dosing eﬃcacy [48–52]. Kim et al. [48] utilized
the BNI pain intensity scale [26] to assess 66 TN patients
treated with a GK maximum dose of 80Gy and 44 TN10 International Journal of Otolaryngology
patients treated with a GK dose of 85Gy. Although the two
groups did not statistically diﬀer in terms of facial rain relief
and procedure-related complications, the authors did report
that patients treated with a GK dose of 85Gy experienced
a more rapid response to treatment when compared to
the patients treated with a GK dose of 80Gy. Arai et al.
[50] analyzed 165 patients with TN treated with a GKRS
dose of 80Gy. Speciﬁcally, the authors divided the patients
into two groups, which diﬀered in the radiation dose rate
received (low-dose rate = 1.21–2.05Gy/min; high-dose rate
= 2.06–3.74Gy/min). Using the BNI pain intensity scale [26]
as a clinical evaluation method, it was reported that the
low-dose-rate group and the high-dose-rate group did not
statistically diﬀer in terms of initial pain relief, maintenance
of pain relief, and clinical complications.
Massager et al. [49] divided 358 patients with TN into
three treatment groups. Patients in group one were treated
with a GK dose <90Gy with no beam channel plugging,
patients in group two were treated with a GK dose equal
to 90Gy with no beam channel plugging, and patients in
group three were treated with a GK dose equal to 90Gy
with beam channel plugging. Although the trend did not
reach full statistical signiﬁcance (P = 0.054), patients in
group three exhibited the highest level of pain relief, while
patients in group one exhibited the lowest level of pain relief.
The authors also observed that the three groups statistically
diﬀered (P<0.0001) in terms of trigeminal nerve dysfunc-
tion, with patients in group three experiencing the highest
rate of mild and bothersome complications and patients
in group one experiencing the lowest rate of mild and
bothersome complications. Similar to the results of Massager
et al. [49], Morbidini-Gaﬀney et al. [52]r e p o r t e dp o s i t i v e
outcomes in patients treated with GK doses >85Gy. The
authors also found that patients treated with two isocenters
were more likely to have superior BNI pain intensity scale
[26] scores during their course of followup when compared
to patients treated with a single isocenter.
Dvoraketal.[51]analyzedGKRSretreatmentdosesin28
patients. The median initial dose was 80Gy, and the median
retreatment dose was 45Gy. Although the authors did not
report any predictors in terms of facial pain control and
patient morbidity, they did compare the results of their study
with seven published retreatment articles and found that
successful levels of pain control (>50%) were signiﬁcantly
correlated with cumulative GKRS doses >130Gy, as well as
new trigeminal nerve dysfunction (>20%).
3.3. Targeting. In addition to dose selection eﬃcacy in select
patient cohorts, the radiosurgical target of CN V is another
subject matter that requires further clinical investigation.
We reviewed three studies [53–55] analyzing speciﬁc GKRS
targeting methods in the treatment of TN and one study [56]
that examined the accuracy of GKRS to its image-guided tar-
get.Matsudaetal.[53]comparedpatientstreatedwithGKRS
targeted at the dorsal root entry zone (59 patients) with
patients whose radiosurgical target was the retrogasserian
zone of the trigeminal nerve (41 patients). With a median
followup of 30 months, the dorsal root entry target group
Table 5: Barrow Neurological Institute pain intensity scale [26].
BNI Class I
No trigeminal pain; no medication
BNI Class II
Some trigeminal pain; no medication
BNI Class IIIa
No trigeminal pain; managed with medication
BNI Class IIIb
Persistent trigeminal pain; managed with medication
BNI Class IV
Some trigeminal pain; not adequately managed with medication
BNI Class V
Severe pain or treatment failure
exhibited statistically superior levels of initial complete pain
remission (P = 0.003) and experienced less complications
than the retrogasserian zone group (P = 0.009). Chen et
al. [54] also reported positive results with the dorsal root
entry zone-targeting approach, with a success rate of 82.8%
and a complication rate of 15%. Park et al. [55]c o m p a r e d
the dorsal root entry zone and retrogasserian zone-targeting
methods in the treatment of 39 patients with medically
refractory TN. The authors reported that the two treatment
arms did not statistically diﬀer in treatment success (BNI
class I-IIIb) with respect to the BNI pain intensity scale
[26]. However, patients treated with the retrogasserian zone-
targeting method experienced a substantially shorter time
of response to GKRS than patients treated with the dorsal
root entry zone-targeting method (P = 0.044). Although
the two groups did not statistically diﬀer with regard to
treatment-related morbidities, it was found that the patients
whose targeting approach was the dorsal root entry zone
experienced a greater amount of bothersome complications
than the retrogasserian zone group.
Massager et al. [56] analyzed the targeting accuracy
of GKRS in 65 patients treated for TN whose six month
followup MRI showed focal contrast enhancement of the
trigeminal nerve. The authors found that the median devi-
ation of the coordinates between the intended radiosurgical
target and the center of contrast enhancement was 0.91mm
in Euclidean space. The median radiation dose ﬁtting into
the contrast enhancement region was determined to be 77 ±
8.7Gy. This small deviation from the GKRS target explains
the high accuracy and precise nature of the machine.
3.4. Measurements of Response to Treatment. The two most
common methods of measuring patient outcomes from
GKRSinthemanagementofTNaretheBarrowNeurological
Institute pain intensity scale [26]( Table 5) and the excellent-
good-fair-poor (EGFP) categorical scale (Table 6). The BNI
pain intensity scale divides patients into one of ﬁve classes,
with a higher class indicating a worse prognosis for the
patient. Patients in BNI class I experience no trigeminal
pain and do not require medication. Patients in BNI class
II experience occasional trigeminal pain but do not requireInternational Journal of Otolaryngology 11
Table 6: Excellent-good-fair-poor categorical scale.
Excellent
Complete pain relief without medication
Good





medication. Patients in BNI class IIIa do not experience
trigeminal pain but require the use of medication. Patients
in BNI class IIIb experience some trigeminal pain that can be
satisfactorily managed with medication. Patients in BNI class
IV experience some trigeminal pain that is not satisfactorily
managed with medication. Patients in BNI class V do not
experience a reduction in pain. The EGFP method catego-
rizes patients into one of four groups. “Excellent” outcomes
are deﬁned as complete pain relief without the need of medi-
cation. “Good” outcomes are deﬁned as complete pain relief
with the need of medication. “Fair” outcomes are deﬁned
as a >50% pain relief rate. “Poor” outcomes are deﬁned as
a <50% pain relief rate or treatment failure.
4. Conclusions
For patients with medically refractory forms of TN, GKRS
has proven to be an eﬀective initial and repeat treatment
option. Cumulative research suggests that patients treated a
single time with GKRS exhibit similar levels of facial pain
control when compared to patients treated multiple times
with GKRS. However, patients treated on multiple occasions
with GKRS are more likely to experience facial numbness
and other facial sensory changes when compared to patients
treated once with GKRS. Although numerous articles have
reported MVD to be superior to GKRS in achieving facial
pain relief, the ﬁndings of these comparison studies are
weakened by the vast diﬀerences in patient age and comor-
bidities between the two studied groups and cannot be
considered conclusive. Further evidence in the form of a
Phase III-randomized trial is needed to conﬁrm the clinical
outcomes of patients treated with either modality. Ques-
tions remain regarding optimal GKRS dosing and targeting
strategies, which warrants further investigation into this
controversial matter.
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